SEC Form 4 · accession 0000899243-18-024909

Deciphera Pharmaceuticals, Inc. · DCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Daniel Lee Flynn

Officer — Chief Scientific Officer

Period of report

Oct 2, 2017

Accepted (ET)

Sep 20, 2018 · 4:19 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001654151

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 2, 2017	C	147,049	—	A	147,049	I	By Biochenomix, LLC

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1	—	Oct 2, 2017	C	22,070	D	—	—	Common Stock	124,695	0	I
Series B-1 Preferred Stock^F1	—	Oct 2, 2017	C	1,494	D	—	—	Common Stock	8,441	0	I
Series B-2 Preferred Stock^F1	—	Oct 2, 2017	C	1,392	D	—	—	Common Stock	7,865	0	I
Series C Preferred Stock^F1	—	Oct 2, 2017	C	1,071	D	—	—	Common Stock	6,048	0	I
Stock Option (Right to Buy)^F2,F3	$1.89	Oct 2, 2017	M	110,727	D	—	Dec 17, 2025	Common Stock	625,607	0	D
Stock Option (Right to Buy)^F4,F2,F3	$1.89	Oct 2, 2017	M	625,607	A	—	Dec 17, 2025	Common Stock	625,607	625,607	D
Stock Option (Right to Buy)^F2,F5	$1.89	Oct 2, 2017	M	24,607	D	—	Dec 17, 2025	Common Stock	139,029	0	D
Stock Option (Right to Buy)^F4,F2,F5	$1.89	Oct 2, 2017	M	139,029	A	—	Dec 17, 2025	Common Stock	139,029	139,029	D
Stock Option (Right to Buy)^F2,F6	$3.95	Oct 2, 2017	M	7,000	D	—	Sep 26, 2026	Common Stock	39,550	0	D
Stock Option (Right to Buy)^F4,F2,F6	$3.95	Oct 2, 2017	M	39,550	A	—	Sep 26, 2026	Common Stock	39,550	39,550	D
Stock Option (Right to Buy)^F2,F7	$6.13	Oct 2, 2017	M	26,835	D	—	Jun 3, 2027	Common Stock	151,617	0	D
Stock Option (Right to Buy)^F4,F2,F7	$6.13	Oct 2, 2017	M	151,617	A	—	Jun 3, 2027	Common Stock	151,617	151,617	D
Stock Option (Right to Buy)^F8	$29.71	Feb 16, 2018	A	68,500	A	—	Feb 15, 2028	Common Stock	68,500	68,500	D

Explanation of responses

F1Represents preferred stock of Deciphera Pharmaceuticals, LLC. Upon the closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into 5.65 shares of common stock of the Issuer.
F2Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b).
F3This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.
F4Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement.
F5This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates.
F6This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates.
F7This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates.
F8This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates.